Evidence map›Paper›PMID 32705273›Full record

ArticleInternational journal of molecular medicine2020

Inhibition of miRNA‑135a‑5p ameliorates TGF‑β1‑induced human renal fibrosis by targeting SIRT1 in diabetic nephropathy.

Juan Zhang, Lian Zhang, Dongqing Zha, Xiaoyan Wu

Open access · hybridAbstract read
In one paragraph

Article in International journal of molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Autophagy and Mitophagy in Diabetic Kidney Disease-A Literature Review.International journal of molecular sciences · 2025
    Review
  11. Review
  12. Review
  13. Article
  14. [The Role of TGF-β1/SMAD in Diabetic Nephropathy: Mechanisms and Research Development].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2023
    Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Juan ZhangDepartment of Nephrology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China.
Lian ZhangDepartment of Nephrology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China.
Dongqing ZhaDepartment of Nephrology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China.
Xiaoyan WuDepartment of Nephrology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China.
Wuhan University · CNZhongnan Hospital of Wuhan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

miRNA‑135a‑5p upregulation has been identified in renal fibrosis in diabetic nephropathy (DN) with an incompletely known mechanism. Previous data showed that Sirtuin 1 (SIRT1) serves as a novel therapeutic target for DN and interact with the transforming growth factor‑β/mothers against decapentaplegic homolog (TGF‑β/Smad) signaling pathway. The aim of this study was to investigate the regulatory relationship between miR‑135a‑5p and SIRT1. The expression of miR‑135a‑5p and SIRT1 was detected using reverse transcription‑quantitative PCR and western blotting. The renal fibrosis and Smad3 signaling pathway were assessed by western blotting, by analyzing protein expression of collegen1A1, α‑smooth muscle actin (α‑SMA), fibronectin (FN), epithelial‑cadherin, Smad3 and phosphorylated Smad3 (p‑Smad3). The target binding between miR‑135a‑5p and SIRT1 was predicted on TargetScan Human software, and confirmed by dual‑luciferase reporter assay and RNA immunoprecipitation. The results demonstrated miR‑135a‑5p is upregulated and SIRT1 was downregulated in the serum and renal tissue of DN patients, and TGFβ1‑induced DN cell models in human HK‑2 and HMCs. Knockdown of miR‑135a‑5p and overexpression of SIRT1 could inhibit TGFβ1‑induced renal fibrosis in vitro. Moreover, SIRT1 was a downstream target for miR‑135a‑5p. Silencing of SIRT1 could abolish the suppressive role of miR‑135a‑5p knockdown in TGFβ1‑induced HK‑2 and HMCs. The TGFβ1 induced p‑Smad3 expression in HK‑2 and HMCs, which could be attenuated by miR‑135a‑5p knockdown via SIRT1. In conclusion, knockdown of miR‑135a‑5p inhibits TGFβ1‑induced renal fibrosis by targeting SIRT1 and inactivating Smad3 signaling, providing a novel insight into miR‑135a‑5p as a potential therapeutic approach for DN.

Indexed as

Cell LineDiabetic NephropathiesDown-RegulationFemaleFibrosisGene Knockdown TechniquesHumansKidneyMaleMicroRNAsMiddle AgedSirtuin 1Transforming Growth Factor beta1Up-RegulationMicroRNAsMIRN135 microRNA, humanSIRT1 protein, humanSirtuin 1TGFB1 protein, humanTransforming Growth Factor beta1

Identifiers

PMID32705273
PMCPMC7387088
OpenAlexW3036449829

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.